It has been revealed in a recent report that the drug firm Ranbaxy has suffered a major setback after Teva, medical firm from Israel, said that they won’t supply the Indian firm with ingredients for the purpose of making copies of Lipitor from the USA.

It was revealed by Ranbaxy, on the other hand, that it shall give part of its benefits from Lipitor U. S, to Teva. It did not however give out any further details about the agreement. Ranbaxy is trying to make its own version of Lipitor, which is going to be available at better competitive prices.

It was further revealed that the patent fight of Lipitor was lost and this is why they are looking for a new generic version of the cholesterol lowering medicine. The name of this generic version is atorvastatin calcium. Pharmacists are of the view that this might result in drastic fall in the prices of the drug, and eventually, the drug will be available at as low as 60 to 80 cents.

"We've been forced away from [prescribing Lipitor] just because of the fact the patients couldn't afford the co-pay or afford to buy if it wasn't covered by their insurance”, revealed Dr. James Smith. It was further revealed that most of the patients were put on medicines for lowering the levels of lipids in their bodies, and Lipitor is one of the most widely used out of these.

The generic versions shall now be available in place of the Lipitor and this might make a lot of difference in the prices. These medicines will be affordable as well as equally functional for the patients in need of them. Patients will not have to bear heavy cost for their medications now.